No Data
CLOUDR: ANNUAL REPORT 2024
Take Care Before Jumping Onto ClouDr Group Limited (HKG:9955) Even Though It's 26% Cheaper
Fully commit to embracing the AI new era, Zhiyun Health (09955) Global Strategy Upgrade 2.0.
Under the guidance of the two major strategies of "Hospital First" and "P2M", in 2024, Zhiyun Health's in-hospital and out-of-hospital solution Business achieved high-quality development.
The new ecology of fiery forging: The "Medical AI + P2M" evolution of Zhi Yun Health (9955.HK) 2.0.
Nowadays, the Medical Industry is at a crossroads of transformation. Driven by both policy guidance and the integration of "AI+" technologies, the industry maintains an overall positive development tone, yet a deep reconstruction of the underlying ecosystem has quietly begun. It is undeniable that the entire Medical industry ecosystem still faces many uncertainties, such as the pressure from the healthcare payment system forming a forcing mechanism and the chain reactions brought about by price adjustments in centralized procurement policies, all of which are being transmitted deeply through the Industry Chain, leading to structural changes in every segment of the industry. In this macro environment, as the trend of population aging becomes increasingly serious, payers, service providers, and suppliers are forming.
ZhiYun Health (09955) exhibits effective results from its AI-driven Global Strategy upgrade with a revenue of 3.49 billion yuan in 2024.
Annual revenue reached 3.49 billion yuan, with a gross margin remaining stable and slightly increasing to 24.7%.
ClouDr Group Limited Reports Increased Losses and Revenue Decline for 2024
